Repligen (RGEN) News Today $160.51 -2.34 (-1.44%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Artemis Investment Management LLP Grows Position in Repligen Co. (NASDAQ:RGEN)Artemis Investment Management LLP raised its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 18.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,832 shares of the biotechnoloJanuary 19 at 8:27 AM | marketbeat.comRepligen Corporation (RGEN) Stock ForecastsJanuary 16, 2025 | ca.finance.yahoo.comRepligen Co. (NASDAQ:RGEN) Receives $185.20 Average Price Target from BrokeragesJanuary 15, 2025 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the thirteen research firms that are covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and eight have issuJanuary 12, 2025 | marketbeat.comRepligen Corp (RGEN) to Present at J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | gurufocus.comRepligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comRepligen Launches CTech SoloVPE PLUS, The Most Advanced UV-based Variable Pathlength SystemJanuary 6, 2025 | markets.businessinsider.comRepligen Corp (RGEN) Launches Advanced SoloVPE PLUS System for BioprocessingJanuary 6, 2025 | gurufocus.comRepligen Corporation Launches CTech™ SoloVPE® PLUS System for Enhanced UV-Based Bioprocessing AnalyticsJanuary 6, 2025 | quiverquant.comRepligen Launches the CTech™ SoloVPE® PLUS SystemJanuary 6, 2025 | globenewswire.comJPMorgan Chase & Co. Sells 9,681,000 Shares of Repligen Co. (NASDAQ:RGEN)JPMorgan Chase & Co. reduced its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 96.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 363,499 shares of the biotechnology company's stock after selling 9,6January 5, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Upgraded at StockNews.comStockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday.January 3, 2025 | marketbeat.comPrincipal Financial Group Inc. Has $18.01 Million Holdings in Repligen Co. (NASDAQ:RGEN)Principal Financial Group Inc. decreased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 30.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 120,991 shares of the biotechnology company's stock after sellingDecember 27, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Holdings Cut by Barclays PLCBarclays PLC reduced its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 87.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,395 shares of the biotechnology company's stock after selling 181,761 shaDecember 23, 2024 | marketbeat.comRepligen Corporation (RGEN) Fell Along with PeersDecember 20, 2024 | insidermonkey.comStockNews.com Downgrades Repligen (NASDAQ:RGEN) to SellStockNews.com downgraded Repligen from a "hold" rating to a "sell" rating in a research note on Thursday.December 19, 2024 | marketbeat.comFranklin Resources Inc. Has $47.55 Million Holdings in Repligen Co. (NASDAQ:RGEN)Franklin Resources Inc. increased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 332,405 shares of the biotechnology company's stock after purchasing an additional 26,668 shares during the pDecember 18, 2024 | marketbeat.comTidal Investments LLC Has $1.66 Million Stake in Repligen Co. (NASDAQ:RGEN)Tidal Investments LLC increased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 142.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,149 shares of the biotechnology company's stock after purchasing anDecember 18, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and eight have assigned aDecember 18, 2024 | marketbeat.comBioLife Solutions appoints Hunt to board of directorsDecember 17, 2024 | markets.businessinsider.comRepligen initiated with a Hold at CanaccordDecember 17, 2024 | markets.businessinsider.comRepligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Canaccord Genuity GroupCanaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday. They issued a "hold" rating and a $165.00 target price on the stock.December 17, 2024 | marketbeat.comRepligen (NASDAQ:RGEN) Earns Hold Rating from Analysts at Canaccord Genuity GroupCanaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday. They issued a "hold" rating and a $165.00 price objective for the company.December 17, 2024 | marketbeat.comBioLife Solutions Appoints Tony J. Hunt to its Board of DirectorsDecember 16, 2024 | prnewswire.comAnalysts Offer Predictions for Repligen FY2025 EarningsRepligen Co. (NASDAQ:RGEN - Free Report) - Investment analysts at William Blair dropped their FY2025 earnings per share estimates for Repligen in a research note issued to investors on Wednesday, December 11th. William Blair analyst M. Larew now anticipates that the biotechnology company will earDecember 16, 2024 | marketbeat.comY Intercept Hong Kong Ltd Acquires Shares of 4,421 Repligen Co. (NASDAQ:RGEN)Y Intercept Hong Kong Ltd bought a new position in Repligen Co. (NASDAQ:RGEN - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,421 shares of the biotechnology company's stock, valued at approximately $658,December 15, 2024 | marketbeat.comWilliam Blair Analysts Raise Earnings Estimates for RepligenRepligen Co. (NASDAQ:RGEN - Free Report) - Investment analysts at William Blair lifted their FY2024 earnings per share (EPS) estimates for Repligen in a research report issued on Wednesday, December 11th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnDecember 13, 2024 | marketbeat.comRepligen Announces Publication of the Company’s 2023 Corporate Sustainability ReportDecember 12, 2024 | finance.yahoo.comRepligen Announces Publication of the Company's 2023 Corporate Sustainability ReportDecember 12, 2024 | globenewswire.comState Street Corp Decreases Stock Position in Repligen Co. (NASDAQ:RGEN)State Street Corp trimmed its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 6.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,623,683 shares of the biotechnology company's stock after selling 113,741December 12, 2024 | marketbeat.comJanus Henderson Group PLC Purchases 21,201 Shares of Repligen Co. (NASDAQ:RGEN)Janus Henderson Group PLC raised its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 848.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,700 shares of the biotechnology company's stoDecember 12, 2024 | marketbeat.comRepligen launches AVIPure dsRNA Clear OPUS columnsDecember 10, 2024 | markets.businessinsider.comSeveral Factors Lifted Repligen Corporation (RGEN) in Q3December 9, 2024 | insidermonkey.comRepligen Corporation Launches AVIPure® dsRNA Clear OPUS® Columns to Enhance mRNA Therapeutics ProductionDecember 9, 2024 | quiverquant.comRepligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed ColumnsDecember 9, 2024 | globenewswire.comTwo Sigma Advisers LP Grows Stock Holdings in Repligen Co. (NASDAQ:RGEN)Two Sigma Advisers LP raised its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 421.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 126,300 shares of the biotechnology company's stock after buying an additional 102,100 shDecember 9, 2024 | marketbeat.com15,500 Shares in Repligen Co. (NASDAQ:RGEN) Acquired by Castleark Management LLCCastleark Management LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,500 shares of the biotechnology company's stock, valued atDecember 8, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Bought by Worldquant Millennium Advisors LLCWorldquant Millennium Advisors LLC raised its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 11.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 50,276 shares of the biotechnology company's stockDecember 8, 2024 | marketbeat.comPolar Asset Management Partners Inc. Invests $580,000 in Repligen Co. (NASDAQ:RGEN)Polar Asset Management Partners Inc. acquired a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 3,900 shares of the biotechnology company's stock, valued aDecember 7, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets trimmed its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 75.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,298 shares of the biotechnology company's stock after selling 44,809December 7, 2024 | marketbeat.comIntech Investment Management LLC Sells 7,662 Shares of Repligen Co. (NASDAQ:RGEN)Intech Investment Management LLC trimmed its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 81.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,803 shares of the biotecDecember 6, 2024 | marketbeat.comPoint72 Asset Management L.P. Buys 9,387 Shares of Repligen Co. (NASDAQ:RGEN)Point72 Asset Management L.P. raised its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 3.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 324,434 shares of the biotechnology compaDecember 5, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 145,254 Shares of Repligen Co. (NASDAQ:RGEN)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 41.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 208,610 shares of tDecember 5, 2024 | marketbeat.comFmr LLC Sells 641,519 Shares of Repligen Co. (NASDAQ:RGEN)Fmr LLC lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 44.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 803,269 shares of the biotechnology company's stock after selling 641,519December 5, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by Miura Global Management LLCMiura Global Management LLC decreased its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 66.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,000 shares of the biotechnology company's stock after sellingDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Invests $1.12 Million in Repligen Co. (NASDAQ:RGEN)Cinctive Capital Management LP acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 7,514 shares of the bioteDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Buys New Shares in Repligen Co. (NASDAQ:RGEN)Erste Asset Management GmbH purchased a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 12,500 shares of the biotechnology company'sDecember 4, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by Bamco Inc. NYBamco Inc. NY reduced its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 3.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 167,019 shares of the biotechnology company's stock after selling 5,December 3, 2024 | marketbeat.comPaloma Partners Management Co Raises Holdings in Repligen Co. (NASDAQ:RGEN)Paloma Partners Management Co boosted its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 267.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,932 shares of the biotechnologyDecember 3, 2024 | marketbeat.comBank of Montreal Can Boosts Holdings in Repligen Co. (NASDAQ:RGEN)Bank of Montreal Can grew its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 34.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,568 shares of the biotechnology company's stock after purchasing an additioDecember 3, 2024 | marketbeat.com Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Media Mentions By Week RGEN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGEN News Sentiment▼0.670.44▲Average Medical News Sentiment RGEN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGEN Articles This Week▼36▲RGEN Articles Average Week Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Biogen News United Therapeutics News Neurocrine Biosciences News Incyte News BioMarin Pharmaceutical News Exact Sciences News Exelixis News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGEN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
